PIPE Deals: How Accredited Investors Buy Public Companies at a Discount

TL;DR: On July 1, 2026, BridgeBio Pharma closed a $933.9 million PIPE (private investment in public equity) with Sixth Street and a KKR affiliate, selling Series A convertible preferred stock at $1,000 a share with a conversion price of $137.79. According to the BridgeBio 8-K filing, the deal closed in days, not months. That speed is the entire pitch of a PIPE: an accredited investor negotiates a fixed price with a public company directly, wires the money, and waits for a resale registration to go effective before selling. You get a discount. You give up liquidity. I want to show you where that trade works and where it turns into a shareholder-killing machine.

The pitch nobody makes in public

Most retail investors have never heard of a PIPE, and most financial media only covers them when a household name closes one. That's a mistake, because PIPEs are one of the few places where an accredited investor can negotiate terms directly with a public company's board instead of buying at whatever price the market hands you. You're not competing with algorithmic traders for a fill. You're sitting across the table from a CFO who needs capital now and is willing to pay for speed.

Here's the contrarian part: the financial press treats PIPEs as a red flag, a sign a company couldn't raise money any other way. Sometimes that's true. But BridgeBio's $933.9 million raise from Sixth Street and KKR isn't a distress signal, it's a negotiated growth financing between two of the largest alternative asset managers in the world and a commercial-stage biopharma company. The same structure that saves a cash-strapped microcap can also be the vehicle a well-capitalized company uses to avoid a dilutive public offering and a six-week SEC review clock. The mechanism is identical. The credit quality of the issuer is what separates a smart allocation from a trap.

What a PIPE actually is

A PIPE is a private placement of stock or convertible securities sold by an already-public company directly to a small group of investors, usually institutions, family offices, or accredited individuals. The company skips the public offering process entirely. There's no S-1 registration before the money changes hands, no SEC comment letters to answer, no roadshow. The deal is negotiated under Securities Act Rule 501(a) of Regulation D, commonly called Reg D, which exempts private securities sales from public registration as long as buyers meet accredited investor income or net worth thresholds.

The trade-off is liquidity. Because the shares are sold privately, investors can't resell them on the open market right away. The company has to file a resale registration statement, an S-1 or S-3, and wait for the SEC to declare it effective. Until that happens, the PIPE investor is locked in. According to the SEC's own FAQ on PIPE transactions, this registration requirement, combined with Rule 144 holding period rules and black-out periods around earnings, is what makes PIPE shares fundamentally different from shares you'd buy on Nasdaq at 10 a.m. on a Tuesday.

In exchange for taking on that illiquidity risk, and for moving fast without the due diligence luxury of a marketed public deal, PIPE investors typically get a discount to the market price. Based on data from Daeryun Law's April 2026 overview of PIPE transaction structures, that discount usually runs 5% to 15% below the reference market price, and stock exchange rules matter here too: both the NYSE and Nasdaq require shareholder approval if the PIPE would dilute existing shareholders by more than 20% of shares outstanding. That 20% threshold is a real ceiling companies negotiate around constantly.

The 2025-2026 deals that show how this actually works

Numbers make this concrete. Here are four real PIPE transactions from SEC filings in 2026, ranging from a mega-cap biopharma financing to a smaller Reg D common stock raise.

Company	Deal Size	Structure	Price / Terms	Investors
BridgeBio Pharma	$933.9 million	Series A convertible preferred stock	$1,000/share, converts at $137.79/share	Sixth Street, a KKR affiliate
Whitehawk Therapeutics	$87.5 million	Common stock plus pre-funded warrants	$3.92/share, resale registration due within 30 days, effective within 60-90 days	Accredited institutional investors
Q32 Bio	$55 million	Common stock plus pre-funded warrants	$8.00/share, resale registration due within 50 days of closing	Accredited investors under Reg D Rule 501(a)
Caring Brands, Inc.	Undisclosed in filing summary	Convertible securities with reset ("AIR") feature	Future share price resets to 90% of the average of the 5 lowest closing prices in 10 days	Not disclosed

Look at the spread in structure. BridgeBio's deal is convertible preferred stock, meaning Sixth Street and KKR get a fixed claim ahead of common shareholders plus the option to convert into common stock later at a set price. That's a senior, negotiated instrument for a company with real revenue and a therapeutics pipeline generating institutional confidence. Q32 Bio and Whitehawk, by contrast, sold straight common stock and pre-funded warrants (warrants where most of the exercise price is paid up front, leaving a nominal cost, often a penny, to actually receive the shares later). Both structures are legitimate. Neither is inherently risky on its face. The risk shows up in the fourth row.

How a PIPE turns into a death spiral

Caring Brands' deal includes what's known in the market as an "AIR" feature, short for adjustable in respect of reset pricing, and it's a textbook version of what traders call a toxic or death-spiral convertible. Here's the mechanic in plain terms: instead of converting at a fixed price like BridgeBio's $137.79, Caring Brands' convertible security resets its conversion price to 90% of the average of the five lowest closing prices over a trailing 10-day window. Think through what that does to incentives. If the stock drops, the conversion price drops with it, so the investor gets more shares for the same dollar amount. More shares outstanding pushes the stock price down further. That lower price becomes the new floor for the next reset calculation. Each cycle manufactures its own justification for the next one. Retail shareholders holding the common stock get diluted repeatedly while the PIPE investor's dollar exposure stays protected, sometimes hedged with short positions against the very stock they're converting into. It's a mechanically self-reinforcing decline, and it's precisely why "toxic convertible" isn't hyperbole, it's a description of the math.

This is also why every PIPE isn't the same trade wearing a different ticker. A fixed-price convertible preferred deal like BridgeBio's has a hard ceiling on dilution because the conversion price doesn't move. A reset-priced convertible like Caring Brands' has no such ceiling. If you're an accredited investor evaluating a PIPE opportunity, or a retail shareholder trying to figure out why a stock you own just filed an 8-K about a new financing, the single most important question is whether the conversion or purchase price is fixed or floating. Fixed price, capped dilution. Floating price tied to market performance, open-ended dilution risk.

Why a company chooses a PIPE over a public offering

Speed and certainty. A registered public offering, even a fast one, involves SEC review, pricing risk during the marketing period, and disclosure of the deal to the entire market before it closes, which can move the stock against the company. A PIPE negotiated under Reg D closes privately, often within days of signing a term sheet, because there's no waiting period for SEC review before the money moves. The company knows exactly how much capital it's getting and at what price before it ever announces the deal publicly. The trade-off sits with existing shareholders. Because the deal is negotiated privately with a small group, current shareholders don't get a vote in most structures (unless the dilution exceeds that 20% Nasdaq/NYSE threshold), and they typically learn the terms only after the 8-K is filed. There's also a real compliance tripwire here: any PIPE investor who receives material nonpublic information, MNPI, about the company during negotiations is legally restricted from trading the stock until that information becomes public, under Regulation FD (Fair Disclosure). Companies structure many PIPEs specifically to avoid ever sharing MNPI with prospective investors, negotiating purely off public information, precisely to sidestep this restriction and let investors keep trading other positions during the process.

What this means if you're an accredited investor looking at a PIPE

If a placement agent or a company brings you a PIPE opportunity, treat it like any other private security, not like a stock you can flip Monday morning. Ask these questions before you wire money:

• Is the conversion or purchase price fixed, or does it float based on future trading prices? A floating "reset" price is the single biggest red flag in convertible PIPE structures.
• How long until the resale registration statement is required to be filed, and how long until the SEC is expected to declare it effective? According to Whitehawk's EDGAR filings, its deal specified 30 days to file and 60-90 days to effectiveness. Until that happens, you can't sell.
• What's the company's cash runway without this raise? A PIPE priced at a steep discount with warrant sweeteners is often a signal the company had limited alternatives.
• Who else is in the deal? Sixth Street and KKR bring their own due diligence teams and negotiating power. A PIPE led by unnamed or thinly capitalized investors carries a different risk profile entirely.
• Does the deal include board seats, information rights, or covenants that current shareholders won't see disclosed until the 8-K drops?

The honest risk section

PIPEs are private securities transactions, and they carry the same fundamental risks as any private placement: illiquidity until registration, no guarantee the SEC declares the resale statement effective on the company's proposed timeline, and full exposure to the underlying company's business risk with no public market to exit into if something goes wrong before your shares are freely tradable. A discount to market price only protects you if the market price holds. If the underlying business deteriorates, a 10% discount at signing can turn into a 60% loss by the time your shares are registered and sellable. Reset-priced convertibles carry an additional layer of risk for anyone other than the PIPE investor itself: if you hold common stock in a company that has issued toxic convertibles, you are structurally exposed to dilution that compounds against you with no natural floor. I am not predicting that any specific company named in this article will experience that outcome. I'm telling you the mechanism exists, it's disclosed in SEC filings in plain language if you read the 8-K, and it has played out publicly in the market before.

The next step

If you're an accredited investor and a PIPE opportunity crosses your desk, don't evaluate it off the press release. Pull the actual 8-K from SEC EDGAR, read the securities purchase agreement exhibit, and find the conversion or reset language yourself. It's usually three or four paragraphs, and it tells you more about the real risk than any summary a placement agent hands you. If you don't know how to read a securities purchase agreement, that's a reasonable thing to ask a securities attorney to walk through with you before you commit capital, not after.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.